AP – Johnson & Johnson will spend USD16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division.
The health care giant said yesterday that it will pay USD380 for each Biomed share and also provide another USD35 per share in cash if some commercial and clinical milestones are met.
Abiomed develops technology that treats coronary artery disease and heart failure.
